Why LivaNova (LIVN) Is Up 11.4% After Raising 2025 Revenue Guidance Despite Lower Net Income

• LivaNova PLC announced its third quarter 2025 financial results on November 5, reporting quarterly sales of US$357.75 million, up from US$318.12 million a year earlier, while net income declined to US$26.78 million from US$32.95 million and the company raised its full-year organic revenue growth guidance to between 9.5% and 10.5%.
• Despite a year-over-year decrease in net income and earnings per share for the quarter, the company signaled confidence in its business outlook by increasing its revenue growth guidance for the full year 2025.
• We’ll assess how LivaNova’s upward revision to its revenue forecast could influence its investment narrative and future growth expectations.

This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

LivaNova Investment Narrative Recap

To own a piece of LivaNova, you need to believe that rising global demand for advanced cardiac and neuromodulation devices will translate into lasting revenue growth, even as healthcare systems intensify pressure on pricing and reimbursement. The recent upward revision in 2025 revenue guidance signals management’s continued optimism, but with net income and earnings per share down year-over-year, the biggest near-term catalyst remains execution on product innovation, while the largest risk is persistent margin pressure from rising R&D and regulatory demands. The latest update does little to alter these fundamentals.

Among recent announcements, the expansion of the Essenz Perfusion System into China stands out, as it aligns tightly with the story behind LivaNova’s revised revenue targets, driven by new market entries and rising procedure volumes that support the bullish guidance. This event underscores the company’s focus on global product rollout as a primary lever for growth.

Yet, in contrast to the focus on innovation, investors should also be aware that sustained high R&D costs could...

Read the full narrative on LivaNova (it's free!)

LivaNova's narrative projects $1.6 billion in revenue and $168.9 million in earnings by 2028. This requires 6.4% yearly revenue growth and a $380.2 million earnings increase from current earnings of -$211.3 million.

Uncover how LivaNova's forecasts yield a $65.00 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Members of the Simply Wall St Community set fair value estimates ranging from US$65 to US$175.87, based on two individual perspectives. While consensus points to growth, healthcare cost pressures remain a significant variable for future performance in this sector.

Explore 2 other fair value estimates on LivaNova - why the stock might be worth just $65.00!

Build Your Own LivaNova Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your LivaNova research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 37 companies in the world exploring or producing it. Find the list for free.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com